AstraZeneca (AZN) Receives a Rating Update from a Top Analyst
In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca, with a price target of £155.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
According to TipRanks, Fernandez is a top 100 analyst with an average return of 29.5% and a 64.71% success rate. Fernandez covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Arcturus Therapeutics, and Cidara Therapeutics.
In addition to Guggenheim, AstraZeneca also received a Buy from Morgan Stanley’s Sarita Kapila in a report issued today. However, on November 25, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).
Based on AstraZeneca’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of p15.19 billion and a net profit of p2.53 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p1.47 billion
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.
Read More on GB:AZN:
Disclaimer & DisclosureReport an Issue
- AstraZeneca price target raised to 15,500 GBp from 14,200 GBp at Guggenheim
- AstraZeneca price target raised to $103 from $93 at Morgan Stanley
- AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports
- AstraZeneca, GSK invited to help shape UK drug pricing regime, Sky News says
